Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018–2021

Trends in carbapenem resistance in Pre-COVID and COVID times in a tertiary care hospital in North India

(2023) Nirupama Chatterjee et al.   Annals of Clinical Microbiology and Antimicrobials

Risk Factors and Outcomes of Patients with Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infection

(2023) Xianzhen Wei et al.   Infection and Drug Resistance

Carbapenemase-producing Pseudomonas aeruginosa –an emerging challenge

(2022) Fred C. Tenover et al.   Emerging Microbes & Infections

Pseudomonas aeruginosa bloodstream infection in patients with hematological diseases: Clinical outcomes and prediction model of multidrug-resistant infections

(2022) Yuanqi Zhao et al.   JOURNAL OF INFECTION

Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015–2019

(2021) Yu-Lin Lee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime–avibactam and ceftolozane–tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary

(2020) Dustin O'Neall et al.   ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA

Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections

(2019) Maddalena Giannella et al.   Open Forum Infectious Diseases